Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients

• Published in: Journal of ovarian research Vol. 4; no. 1; p. 20
• Main Authors: Felisiak-Golabek, Anna, Rembiszewska, Alina, Rzepecka, Iwona K, Szafron, Lukasz, Madry, Radoslaw, Murawska, Magdalena, Napiorkowski, Tomasz, Sobiczewski, Piotr, Osuch, Beata, Kupryjanczyk, Jolanta
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.11.2011; BioMed Central; BMC
• Subjects: Apoptosis; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Health aspects; Hospitals; Ovarian cancer; Physiological aspects; Prognosis; Risk factors; survivin; taxol; TP53; Tumor proteins; Poland
• ISSN: 1757-2215; 1757-2215
• DOI: 10.1186/1757-2215-4-20

Survivin is an inhibitor of apoptosis and a regulator of mitotic progression. TP53 protein is a negative transcriptional regulator of survivin. The aim of our study was to evaluate the clinical significance of survivin expression in advanced stages ovarian cancer with respect to the TP53 status. Survivin and TP53 expression was evaluated immunohistochemically in 435 archival samples of ovarian carcinomas (244 patients were treated with platinum/cyclophosphamide-PC/PAC; 191-with taxane-platinum (TP) agents). Univariate and multivariate statistical analyses were performed in patients groups divided according to the administered chemotherapeutic regimen, and in subgroups with and without TP53 accumulation (TP53+ and TP53-, respectively). Nuclear and cytoplasmic survivin expression was observed in 92% and 74% of the carcinomas, respectively. In patients treated with TP, high nuclear survivin expression decreased the risk of disease recurrence and death, and increased the probability of high platinum sensitivity (p < 0.01), but only in the TP53(+) group, and not in the TP53(-) group. It appears that TP53 status determines the clinical importance of nuclear survivin expression in taxane-platinum treated ovarian cancer patients.